Description

Abirapro 250 mg (Abiraterone acetate) belongs to a group of hormonal therapeutics utilized against prostate cancer in adults. Abirapro 250 mg (Abiraterone acetate) is indicated in prostate cancer patients wherein other chemotherapeutic options have failed. Additionally, it is specified in asymptomatic patients where other hormonal therapies were unsuccessful and chemotherapy was not employed.

It targets the unnecessary production of testosterone (a male hormone) used in cancer cell growth. It inhibits the testosterone triggering proteins (CYP17A1 enzyme), thereby decreasing the cancer toll on the body.

This medicine is administered orally without food. 4 tablets of 250 mg (1000 mg) once daily are taken along with 5 mg prednisone twice daily. When used together, Abirapro (Abiraterone acetate) impart advantages like,

Abirapro

Lowers the antigen growth that stimulates prostate cancer
Keeps prostate cancer under control
Rectifies hypertension as a side-effect
Induces hunger for a stable diet
Increases duration of life-span
Delays or rectifies common symptoms such as pain and tiredness
General warnings associated with Abirapro 250 mg (Abiraterone acetate):
Avoid food for at least 2 hours prior and 1 hour after the dose
Avoid crushing or swallowing tablets without water
Avoid grapefruit juice as it triggers unwanted side-effects
Avoid having intercourse or use condom whenever necessary for 1st week after treatment

Side-effects associated with Abirapro 250 mg (Abiraterone acetate):

Serious side-effects:

• High blood pressure (Hypertension)
• Low levels of potassium in the blood (Hypokalemia)
• Retention of fluid (Edema)

Common side-effects:

• Tiredness
• Pain in the joints
• Nausea
• Swollen legs
• Feeling uncomfortably hot (Hot flush)
• Diarrhea
• Vomiting
• Infected nose, sinuses, or throat (Cold)
• Cough
• Headache
• Low red blood cells (Anemia)
• Discomfort in muscles
• Indigestion
• Shortness of breath (Dyspnea)
• Upper respiratory tract and urinary tract infection

Laboratory side-effects:

• Low levels of phosphate (Hypophosphatemia)
• Decreased count of RBCs in the blood (Anemia)
• High levels of fat molecules (triglycerides) (hypertriglyceridemia)
• Increased volumes of cholesterol (hypercholesterolemia), and sugars (hyperglycemia)

Note: Abirapro 250 mg (Abiraterone acetate) might show other side-effects as well. Refer your healthcare provider for more updates regarding the drug.

Other clinical warnings associated with Abirapro 250 mg (Abiraterone acetate):
There are certain conditions wherein doctors need to be informed. These conditions include,

Heart diseases/failure
Arrhythmia (Carry out blood tests every month)
Complications of the liver (Hepatoxicity) with symptoms like yellow coloured skin and eyes, dark coloured urine, severe nausea and vomiting
Reduced density of bones
High amounts of stress
Absence of potassium in the system (Adrenocortical insufficiency)
Embryo-fetal toxicity
Abirapro 250 mg (Abiraterone acetate) is also available in these countries: (South East Asia, South America, Eastern Europe, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic, Slovenia, Malaysia, Indonesia, Philippines, Venezuela and Korea.) and many more…